Dedicated to
Breaking Through

At Libra Therapeutics, we’re taking a new approach to fighting neurodegeneration and meeting one of health’s greatest needs.

Our Life’s Work Is to Find Better Treatments

We’ve experienced first-hand the debilitating effects of neurodegeneration, and we’re dedicated to doing our part by leading new perspectives and meaningful breakthroughs in drug development for these devastating diseases.

OUR TEAM

Leadership

Shawn Scranton, PharmD

Chief Executive Officer & President, Libra Therapeutics
Isaac Veinbergs, PhD

Chief Business Officer, Libra Therapeutics
Isaac Veinbergs, Ph.D., is the President and Chief Executive Officer at Libra Therapeutics, bringing over 25 years of experience in research and development, corporate development, and executive management in the BioPharma industry. Isaac began his career as a scientist with Acadia Pharmaceuticals. He has served in leadership roles at FoldRx Pharmaceuticals, Amgen, and Elan where he oversaw drug discovery programs, operations, and multiple teams. His research and leadership has contributed to multiple INDs and NDAs, and his work includes approaches in neurodegeneration, pain, and psychiatry. Isaac then transitioned to the corporate side of the business and served as Head of Research Operations and Business Development at Brains On-Line and then as Global Head of Business Development and External Innovation of Neurosciences at Sanofi Genzyme. Isaac then returned to Acadia as Head of Corporate Development. Isaac holds a Ph.D. in molecular pathology from UC San Diego School of Medicine.
Martin Gill, PhD

Senior Vice President, Head of Research, Libra Therapeutics

Board of Directors

Shawn Scranton, PharmD

Chief Executive Officer & President, Libra Therapeutics
Casey Cunningham, MD

Partner and Chief Scientific Officer of Santé Ventures
Fei Shen, PhD

Managing Director
Boehringer Ingelheim Venture Fund USA
Gene Kinney, PhD

Chairman of the Board, Libra Therapeutics
President and Chief Executive Officer, Prothena
Sourav Kole, PhD

Managing Director
Dolby Family Ventures
Board observer
Stefan Lohmer, PhD

Founder and Chief Executive Officer, AXXAM
Henning Steinhagen, PhD, MBA

Venture Partner, Epidarex Capital
Daguang Wang, PhD

Managing Director
Yonjin Venture LLC

Scientific Advisory Board

Don Cleveland, PhD

Professor, Molecular and Cell Medicine
Head, Laboratory of Cell Biology, UCSD
Ludwig Institute for Cancer Research
Friedrich Metzger, PhD

Chief Executive Officer, Versemeb
John Ravits, MD

Professor of Clinical Neurosciences
Department of Neuroscience, UCSD
John Renger, PhD

Chief Science Officer, Cerevel Therapeutics
Clotilde Lagier Tourenne, MD, PhD

Assistant Professor of Neurology, MGH, Harvard
Associate Member of the Broad Institute

Shape the Future
of the Mind

Join a highly experienced, passionate team discovering novel ways to change the outcome for millions.

If you share a passion for neuroscience, drug discovery and ultimately, having a dramatic impact on improving patient lives or to apply for an open position, please email opportunities@libratherapeutics.com and provide a CV/resume and statement of interest.

Have Questions?

Restoring a Disrupted
Equilibrium

We’re developing novel therapeutics capable of increasing the body’s natural ability to break down and clear away aggregated proteins and dysfunctional organelles, while also inhibiting key biological mechanisms that contribute to ALS and other degenerative disorders.

The result is an essential return to balance within the body.

VIEW OUR PIPELINE

Dedicated to Breaking Through